Alliqua's listing on NASDAQ this week will increase the wound care provider's visibility in the market, and ultimately increase its shareholder base, says the company's CEO David Johnson. Shares of the micro-cap biotech have risen 25% so far in 2014 after the company transformed itself in 2013 with a reverse stock split, new management and a major investment from biotech giant Celgene to further its Biovance product line.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Too Bearish Too Soon? Your Reality Check from Real Money's Helene Meisler

Too Bearish Too Soon? Your Reality Check from Real Money's Helene Meisler

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: This Is a Sad Time for Southwest Airlines

Jim Cramer: This Is a Sad Time for Southwest Airlines

Video: Jim Cramer on Advanced Micro Devices, Chipotle and Southwest Airlines

Video: Jim Cramer on Advanced Micro Devices, Chipotle and Southwest Airlines